Alnylam cuts Amvuttra sales guidance as demand shifts, hurting stock
Alnylam cuts Amvuttra sales guidance as demand shifts, hurting stock. Reported by Endpoints News on 2026-07-30.
Browse all past biotechnology intelligence, clinical developments, and industry updates.
Archived Updates
Alnylam cuts Amvuttra sales guidance as demand shifts, hurting stock. Reported by Endpoints News on 2026-07-30.
Alnylam shares tank 29% as Amvuttra disappoints
Aspen Neuroscience Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel (ANPD001) to Treat Parkinson's Disease
AtaiBeckley attracted co-development and royalty offers before $2.8B Lilly deal. Reported by Endpoints News on 2026-07-30.
Attovia, Braveheart and Vogenx seek more than $500M via IPOs
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store. Reported by BioSpace on 2026-07-30.
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays. Reported by BioSpace on 2026-07-30.
BMS CEO doesn’t ‘feel any compulsion to chase deals’
Braveheart Bio targets $1.2 billion valuation in US IPO
Capricor’s data clash and a fugitive in the C-suite
CereVasc Opens New Massachusetts Facility in Preparation for eShunt® System Commercialization
Chronically ill people face confusion over new Medicaid work rules and ‘medically frail’ exemption
CMS Validates Andor Health's AI-Native Clinical Services Operating Platform
Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts. Reported by BioSpace on 2026-07-30.
Ebola outbreak nears milestone, while a vaccine remains months away. Reported by STAT News on 2026-07-30.